Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03862989
Other study ID # 1819/14
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date May 1, 2021
Est. completion date November 1, 2021

Study information

Verified date December 2021
Source University of Exeter
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Each year in the UK, approximately 150,000 people have a heart attack when the blood supply to their heart is compromised. As a result, affected regions of the heart can become diseased and scarred. In a healthy person, electrical waves propagate across the heart in a regulated pattern which triggers contraction to pump blood around the body. The scar tissue that forms as a result of a heart attack can disrupt the propagation of the electrical waves. If significant disruptions occur, blood cannot be pumped out of the body effectively, leading to sudden death. Ablation therapy aims to eliminate areas of diseased tissue that cause disruption to the heart rhythm, by applying radiofrequency using catheters inserted into the heart. The most accurate techniques used to locate the region to ablate require the induction of dangerous heart rhythms, which are only inducible in about 65% of people. Pace mapping is a technique used to locate regions to ablate, which can be performed during normal heart rhythm. ECG data, which records electrical signals from the heart, is collected when the patient has an abnormal heart rhythm. From this template ECG, a clinician can tell the approximate location of the diseased tissue. A catheter is directed to that location, the heart stimulated, and another ECG, called the paced ECG is recorded. If the paced ECG matches the template ECG, it is assumed that the heart was paced in the location that requires ablation. Current ablation techniques are difficult, time consuming, and inaccurate. As a result, the procedure may work in only half of all patients, and result in unnecessary damage to healthy tissue, leading to later impairment of heart function. The CPS project's overall goal is to increase the success rates of ablation therapy by improving the accuracy and efficiency of locating the optimal region of tissue to eliminate during the pace mapping procedure. Increasing ablation therapy success rates will mean that patients will be unlikely to suffer from future heart rhythm disorders as a result of their heart attack, increasing the life expectancy of heart attack patients. Excess damage caused to the heart as a result of unnecessary ablation lesions will be limited, decreasing the likelihood of future complications. In addition, dangerous heart rhythms do not need to be induced in the patient, significantly decreasing the risk of death during the treatment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 1, 2021
Est. primary completion date November 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - post-myocardial infarction ventricular tachycardia diagnosis - scheduled to undergo radiofrequency catheter ablation as either emergency or elective case Exclusion Criteria: - Unable to perform pace mapping during ablation procedure - Unable to terminate VT thus unable to provide data regarding successful ablation lesion sites - Intracardiac thrombus

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Radiofrequency catheter ablation
A catheter is inserted into the heart and signals are recorded from the heart whilst at rest or whilst being stimulated by a catheter, in order to determine the site to ablate. Radiofrequency is then delivered to the target site in order to disrupt the pathological electrical activation which is causing the abnormal heart rhythm.

Locations

Country Name City State
United Kingdom Bristol Heart Institute Bristol

Sponsors (4)

Lead Sponsor Collaborator
University of Exeter EPSRC, Medical Research Council, University Hospitals Bristol and Weston NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy of scar region prediction The accuracy with which we can predict the region of the scar using the developed algorithm, in order to direct initial catheter placement to begin pace mapping. 6 weeks
Primary Speed in determining optimal ablation target site The speed with which the optimal target site for ablation is determined by the developed algorithm 6 weeks
Primary Accuracy in determining optimal ablation target site The accuracy with which the optimal target site for ablation is determined by the developed algorithm 6 weeks